What is this study trying to find out about acute respiratory distress syndrome in traumatic brain injury?

This study aims to assess whether the fibrinogen-to-albumin ratio measured early after ICU admission can predict the development of acute respiratory distress syndrome in patients with traumatic brain injury. Researchers hope this biomarker can help identify patients at risk of this serious complication. The study is sponsored by Tanta University.

Who may be eligible for this traumatic brain injury clinical trial?

Adults aged 18 years or older admitted to the ICU within 24 hours of traumatic brain injury may be eligible. Participants must have fibrinogen and albumin levels measured within the first 24 hours and be expected to remain under hospital care. This trial is open to all genders. Please review eligibility criteria for more details.

Is there any cost to participate in this traumatic brain injury clinical trial?

Study-related care, including blood tests and all trial assessments, is provided at no cost. However, personal travel and related expenses are not guaranteed to be covered and may vary. Participants can expect all necessary testing to be done as part of their hospital stay.

Actively Recruiting

Age: 18Years +

All Genders

ID07664358

Predicting Acute Respiratory Distress Syndrome in Adults With Traumatic Brain Injury Using Fibrinogen-to-Albumin Ratio

Led by Tanta University · Updated on 2026-07-06

350

Participants Needed

Research Sites

13 weeks

Total Duration

AI-Summary

What this Trial Is About

Traumatic brain injury is a significant cause of illness and death worldwide, often leading to systemic inflammation and secondary organ problems in critically ill patients. Acute respiratory distress syndrome ARDS is a serious complication affecting 19-30% of severe traumatic brain injury patients, usually developing within the first week after injury. This study evaluates the fibrinogen-to-albumin ratio as a potential early predictor of ARDS in adults with traumatic brain injury. The study involves measuring fibrinogen and albumin levels from routine blood samples taken within 24 hours of ICU admission. The fibrinogen-to-albumin ratio FAR is calculated by dividing fibrinogen by albumin levels. Patients are categorized into groups based on whether they develop ARDS within 7 days according to Berlin criteria. The study does not involve administering treatments but focuses on diagnostic blood tests. Participants will be followed during their ICU stay, with researchers assessing the accuracy of early fibrinogen-to-albumin ratio measurements to predict ARDS development within 7 days. Secondary outcomes include ARDS incidence and severity, duration of mechanical ventilation, ICU stay length, mortality, and neurological outcomes up to 90 days after injury. Consent is obtained from authorized representatives, and follow-up is expected while participants remain hospitalized.

CONDITIONS

Brief Title

Fibrinogen-to-Albumin Ratio as a Predictor of Acute Respiratory Distress Syndrome in Traumatic Brain Injury

Who Can Participate

Age: 18Years +

All Genders

Eligibility Criteria

You may qualify if you...

Patients 18 years or older admitted to the ICU with traumatic brain injury
Admission to the ICU within 24 hours of injury
Patients expected to remain under hospital care for follow-up
Availability of fibrinogen and albumin measurements within 24 hours of ICU admission
Informed consent obtained from a legally authorized representative

You will not qualify if you...

Advanced chronic liver disease, nephrotic syndrome, or protein-losing enteropathy
Pre-existing acute respiratory distress syndrome on admission
Receipt of albumin, fibrinogen concentrate, or cryoprecipitate before admission sampling
Use of anticoagulant or fibrinolytic therapy before admission
Active malignancy or severe systemic infection at admission
Direct severe lung injury
Pregnancy
Refusal of consent

Research Team

Eman M Taher, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here